Gastric antisecretory drug market is anticipated to grow at a CAGR of 3.8% during the forecast period. Antisecretory drugs assist in reducing the normal rate of secretion of a body fluid that reduces acid secretion into the stomach. Such drugs include antimuscarinic drugs, H2-receptor antagonists and proton-pump inhibitors. The surging prevalence of gastrointestinal disorders such as dyspepsia, peptic ulcer, and gastroesophageal reflux is the prominent factor that has boosted the demand for gastric antisecretory drugs. In the US, peptic ulcer disease affects approximately 4.6 million people annually, with an estimated 10% of the US population having evidence of a duodenal ulcer at some time, according to Harvard Health. Apart from these, the growing prevalence of stress-induced ulcers due to changing lifestyles and diet, increasing smoking rate, and progressive population of geriatrics is anticipated to promote the growth of the global gastric antisecretory drug market. Moreover, significant partnerships, collaborations and new product development by the market players are likely to generate new growth opportunities for the market.
Get Free Sample link @ https://www.omrglobal.com/request-sample/gastric-antisecretory-drug-market
For instance, in July 2021, Shandong Luoxin Pharmaceutical Group Stock Co., a subsidiary of Luoxin Pharmaceutical Group Stock Co., Ltd. signed a cooperation agreement with South Korea-based HK Inno. N Corp. for the development, manufacture, and commercialization of Tegoprazan injections in China. Tegoprazan injections have mainly been developed for the treatment of acid-related gastrointestinal diseases such as gastroesophageal reflux disease (GERD) and upper gastrointestinal bleeding as well as for the prevention of stress gastric mucosa injury. Similar, in July 2020, Cadila Pharmaceuticals Ltd. launched Esomeprazole tablets for the treatment of Hyperacidity & Drug Induced Gastritis under the brand name Esiloc. Esomeprazole which is a proton pump inhibitor (PPI), acts on the luminal surface of gastric parietal cells, resulting in inhibition of acid secretion. Esomeprazole provides higher rates of healing of erosive GERD and sustained resolution of heartburn in patients.
A full report of Gastric Antisecretory Drug Market available @ https://www.omrglobal.com/industry-reports/gastric-antisecretory-drug-market
- Market Coverage
- Market number available for – 2022-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered- By Source, By Product Type, By Applications
- Competitive Landscape- Archer Daniels Midland Co., Ingredion Inc., Kerry Group Plc, Cargill Inc., and others
Market Segmentation
Global Gastric Antisecretory Drug Market by Type
- H2-receptor Antagonists
- Gastric Proton Pump Inhibitors
- Others
Global Gastric Antisecretory Drug Market by Application
- Dyspepsia
- Peptic Ulcer
- Gastroesophageal Reflux
- Others
Global Gastric Antisecretory Drug Market by End-User
- Hospital
- Clinic
- Others
Regional Analysis
- North America
- United States
- Canada
- Europe
- UK
- Germany
- Italy
- Spain
- France
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Rest of the World
- Latin America
- Middle East & Africa
Company Profiles
- ALTANA Group
- AstraZeneca plc
- Bayer AG
- Cadila Pharmaceuticals
- Cheplapharm Arzneimittel GmbH
- Cipla Inc.
- Eisai Co., Ltd
- Luoxin Group
- Pfizer, Inc.
- Novartis International AG
- SANIS Health Inc.
- Sanofi-Aventis U.S. LLC
- Shandong Luoxin Pharmaceutical Group Stock co., ltd
- Takeda Pharmaceutical Co. Ltd.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global gastric antisecretory drug market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/gastric-antisecretory-drug-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404
